1
|
Ivanov VM, Krivtsov AM, Smirnov AY, Grebenkov VG, Surov DA, Korzhuk MS, Strelkov SV, Ivanova EG. Experience in the Application of Augmented Reality Technology in the Surgical Treatment of Patients Suffering Primary and Recurrent Pelvic Tumors. J Pers Med 2023; 14:19. [PMID: 38248720 PMCID: PMC10821072 DOI: 10.3390/jpm14010019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2023] [Revised: 12/11/2023] [Accepted: 12/14/2023] [Indexed: 01/23/2024] Open
Abstract
Surgical treatment of locally spread tumors in pelvic organs remains an urgent and complicated oncological problem. The recurrence rate after radical treatment ranges from 15.1% to 45.2%. The key to successful and safe surgical intervention lies in meticulous planning and intraoperative navigation, including the utilization of augmented reality (AR) technology. This paper presents the experience of clinically testing an AR technology application algorithm in the surgical treatment of 11 patients. The main stages of the algorithm are described. Radical operations incorporating intraoperative AR technology with favorable outcomes were performed on eight patients. One patient underwent a palliative intervention, while two patients did not undergo surgery. The testing of the algorithm for the application of AR technology in the surgical treatment of primary and recurrent pelvic tumors demonstrated both a technical possibility and reproducibility of this algorithm and the AR technology itself in clinical practice.
Collapse
Affiliation(s)
- Vladimir M. Ivanov
- Higher School of Theoretical Mechanics, Peter the Great St. Petersburg Polytechnic University, 195251 Saint Petersburg, Russia; (A.M.K.); (A.Y.S.); (E.G.I.)
| | - Anton M. Krivtsov
- Higher School of Theoretical Mechanics, Peter the Great St. Petersburg Polytechnic University, 195251 Saint Petersburg, Russia; (A.M.K.); (A.Y.S.); (E.G.I.)
| | - Anton Yu. Smirnov
- Higher School of Theoretical Mechanics, Peter the Great St. Petersburg Polytechnic University, 195251 Saint Petersburg, Russia; (A.M.K.); (A.Y.S.); (E.G.I.)
| | - Vladimir G. Grebenkov
- Naval Surgery Chair, S. M. Kirov Military Medical Academy, 194044 Saint Petersburg, Russia; (V.G.G.); (D.A.S.); (M.S.K.)
| | - Dmitry A. Surov
- Naval Surgery Chair, S. M. Kirov Military Medical Academy, 194044 Saint Petersburg, Russia; (V.G.G.); (D.A.S.); (M.S.K.)
- Coloproctology Department, Saint-Petersburg I. I. Dzhanelidze Research Institute of Emergency Medicine, 192242 Saint Petersburg, Russia
| | - Michail S. Korzhuk
- Naval Surgery Chair, S. M. Kirov Military Medical Academy, 194044 Saint Petersburg, Russia; (V.G.G.); (D.A.S.); (M.S.K.)
- N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia
| | - Sergey V. Strelkov
- Flinders Street Campus, Torrens University, Melbourne, VIC 3000, Australia;
| | - Elena G. Ivanova
- Higher School of Theoretical Mechanics, Peter the Great St. Petersburg Polytechnic University, 195251 Saint Petersburg, Russia; (A.M.K.); (A.Y.S.); (E.G.I.)
| |
Collapse
|
2
|
Wang J, Ben-David R, Mehrazin R, Yang W, Tewari AK, Kyprianou N. Novel signatures of prostate cancer progression and therapeutic resistance. Expert Opin Ther Targets 2023; 27:1195-1206. [PMID: 38108262 DOI: 10.1080/14728222.2023.2293757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Accepted: 12/07/2023] [Indexed: 12/19/2023]
Abstract
INTRODUCTION The extensive heterogeneity of prostate cancer (PCa) and multilayered complexity of progression to castration-resistant prostate cancer (CRPC) have contributed to the challenges of accurately monitoring advanced disease. Profiling of the tumor microenvironment with large-scale transcriptomic studies have identified gene signatures that predict biochemical recurrence, lymph node invasion, metastases, and development of therapeutic resistance through critical determinants driving CRPC. AREAS COVERED This review encompasses understanding of the role of different molecular determinants of PCa progression to lethal disease including the phenotypic dynamic of cell plasticity, EMT-MET interconversion, and signaling-pathways driving PCa cells to advance and metastasize. The value of liquid biopsies encompassing circulating tumor cells and extracellular vesicles to detect disease progression and emergence of therapeutic resistance in patients progressing to lethal disease is discussed. Relevant literature was added from PubMed portal. EXPERT OPINION Despite progress in the tumor-targeted therapeutics and biomarker discovery, distant metastasis and therapeutic resistance remain the major cause of mortality in patients with advanced CRPC. No single signature can encompass the tremendous phenotypic and genomic heterogeneity of PCa, but rather multi-threaded omics-derived and phenotypic markers tailored and validated into a multimodal signature.
Collapse
Affiliation(s)
- Jason Wang
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Reuben Ben-David
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Reza Mehrazin
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Wei Yang
- Department of Pathology, Stony Brook University, New York, NY, USA
| | - Ashutosh K Tewari
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Natasha Kyprianou
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Pathology & Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| |
Collapse
|
3
|
Vornicescu C, Șenilă SC, Bejinariu NI, Vesa ȘC, Boșca AB, Chirilă DN, Melincovici CS, Sorițău O, Mihu CM. Predictive factors for the recurrence of surgically excised basal cell carcinomas: A retrospective clinical and immunopathological pilot study. Exp Ther Med 2021; 22:1336. [PMID: 34630690 PMCID: PMC8495561 DOI: 10.3892/etm.2021.10771] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Accepted: 07/29/2021] [Indexed: 12/16/2022] Open
Abstract
Basal cell carcinoma (BCC) is the most frequent form of skin cancer and is not a tumor with a lethal outcome if diagnosed and treated adequately. The gold standard for treatment is surgical excision with histologically safe margins. Even so, tumors excised with free margins may recur after a period of time. The identification of predictive factors for the recurrence of BCCs besides the localization, size and aggressive histology may be useful for the clinician. The aim of the present study was to identify clinical and pathological factors associated with recurrence in tumors with histologically free margins and assess via immunohistochemical staining, the expression of glioma-associated oncogene homolog 1 (GLI1), yes-associated protein (YAP), connective tissue growth factor (CTGF) and E-cadherin as they are involved in the development of BCCs, in the hope of identifying markers that are predictive for recurrence. In total, 8 recurrent BCCs and 38 non-recurrent tumors were analyzed. A Breslow index >2 (Se 100.0%, Sp 67.5%, P=0.008), Clark level >3 (Se 100.0%, Sp 47.5%, P<0.001), and excision margins both lateral (Se 87.5%, Sp 60.0%, P=0.04) and deep (Se 75.0%, Sp 82.5%, P<0.001) free from tumoral cells ≤1 mm proved to be predictive for recurrence in the present study. Recurrence may appear even after more than 3 years since the initial excision (Se 87.50%, Sp 70.0%, P<0.001). The expression levels of GLI1, YAP and E-cadherin were not different in the recurrent vs. non-recurrent BCCs. However, the low expression of CTGF may indicate a tumor with a higher aggressiveness. In conclusion, close follow-up of patients with excised BCCs at least annually is recommended and re-excision should be taken into consideration for locally advanced tumors especially if they are located in high-risk areas or those with histologically free margins <1 mm.
Collapse
Affiliation(s)
- Corina Vornicescu
- Department of Morphological Sciences-Histology, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania
| | - Simona Corina Șenilă
- Department of Dermatology, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.,Department of Dermatology, Emergency Clinical County Hospital, 400006 Cluj-Napoca, Romania
| | - Nona Ionela Bejinariu
- Department of Pathology, Santomar Oncodiagnostic, 'Regina Maria' Private Healthcare Network, 400664 Cluj-Napoca, Romania
| | - Ștefan Cristian Vesa
- Department of Pharmacology, Toxicology and Clinical Pharmacology, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania.,Department of Internal Medicine, Out-patient's Clinic Infectious Disease Hospital, 400348 Cluj-Napoca, Romania
| | - Adina Bianca Boșca
- Department of Morphological Sciences-Histology, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania
| | - Daciana Narcisa Chirilă
- Department of Surgery, Vth Surgical Clinic, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400139 Cluj-Napoca, Romania.,Department of Surgery, Clinical Municipal Hospital, 400139 Cluj-Napoca, Romania
| | - Carmen Stanca Melincovici
- Department of Morphological Sciences-Histology, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.,Department of Radiology, Emergency Clinical County Hospital, 400006 Cluj-Napoca, Romania
| | - Olga Sorițău
- Laboratory of Tumor Biology and Radiobiology, 'Prof. Dr. Ion Chiricuţă' Oncology Institute, 400015 Cluj-Napoca, Romania
| | - Carmen Mihaela Mihu
- Department of Morphological Sciences-Histology, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.,Department of Radiology, Emergency Clinical County Hospital, 400006 Cluj-Napoca, Romania
| |
Collapse
|
4
|
Makarevic A, Rapp C, Dettling S, Reuss D, Jungk C, Abdollahi A, von Deimling A, Unterberg A, Herold-Mende C, Warta R. Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma. Int J Mol Sci 2020; 21:E7801. [PMID: 33096928 DOI: 10.3390/ijms21207801] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 10/14/2020] [Accepted: 10/17/2020] [Indexed: 11/16/2022] Open
Abstract
Most gliomas are associated with a fatal prognosis and remain incurable because of their infiltrative growth. Consequently, the addition of immunotherapy to conventional therapy may improve patient outcomes. Here, we analyzed T-cell infiltration and, therefore, a major prerequisite for successful immunotherapy in a series of primary (n = 78) and recurrent (n = 66) isocitrate dehydrogenase (IDH)-mutant glioma and their changes following treatment with radio- and/or chemotherapy. After multicolor immunofluorescence staining, T cells were counted in entire tumor sections using a software-based setup. Newly diagnosed diffuse IDH-mutant gliomas displayed a median T-cell infiltration of 0.99 T cells/mm2 (range: 0-48.97 CD3+ T cells/mm2), which was about two-fold increased for CD3+, helper, and cytotoxic T cells in recurrent glioma. Furthermore, T-cell infiltration of recurrent tumors was associated with the type of adjuvant treatment of the primary tumor. Interestingly, only glioma patients solely receiving radiotherapy presented consistently with increased T-cell infiltration in their recurrent tumors. This was confirmed in a subset of 27 matched pairs. In conclusion, differences in the T-cell infiltration of primary and recurrent gliomas were demonstrated, and evidence was provided for a beneficial long-term effect on T-cell infiltration upon treatment with radiotherapy.
Collapse
|
5
|
Bulubas L, Sardesh N, Traut T, Findlay A, Mizuiri D, Honma SM, Krieg SM, Berger MS, Nagarajan SS, Tarapore PE. Motor Cortical Network Plasticity in Patients With Recurrent Brain Tumors. Front Hum Neurosci 2020; 14:118. [PMID: 32317952 PMCID: PMC7146050 DOI: 10.3389/fnhum.2020.00118] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Accepted: 03/16/2020] [Indexed: 12/15/2022] Open
Abstract
Objective: The adult brain’s potential for plastic reorganization is an important mechanism for the preservation and restoration of function in patients with primary glial neoplasm. Patients with recurrent brain tumors requiring multiple interventions over time present an opportunity to examine brain reorganization. Magnetoencephalography (MEG) is a noninvasive imaging modality that can be used for motor cortical network mapping which, when performed at regular intervals, offers insight into this process of reorganization. Utilizing MEG-based motor mapping, we sought to characterize the reorganization of motor cortical networks over time in a cohort of 78 patients with recurrent glioma. Methods: MEG-based motor cortical maps were obtained by measuring event-related desynchronization (ERD) in ß-band frequency during unilateral index finger flexion. Each patient presented at our Department at least on two occasions for tumor resection due to tumor recurrence, and MEG-based motor mapping was performed as part of preoperative assessment before each surgical resection. Whole-brain activation patterns from first to second MEG scan (obtained before first and second surgery) were compared. Additionally, we calculated distances of activation peaks, which represent the location of the primary motor cortex (MC), to determine the magnitude of movement in motor eloquent areas between the first and second MEG scan. We also explored which demographic, anatomic, and pathological factors influence these shifts. Results: The whole-brain activation motor maps showed a subtle movement of the primary MC from first to second timepoint, as was confirmed by the determination of motor activation peaks. The shift of ipsilesional MC was directly correlated with a frontal-parietal tumor location (p < 0.001), presence of motor deficits (p = 0.021), and with a longer period between MEG scans (p = 0.048). Also, a disengagement of wide areas in the contralesional (ipsilateral to finger movement) hemisphere at the second time point was observed. Conclusions: MEG imaging is a sensitive method for depicting the plasticity of the motor cortical network. Although the location of the primary MC undergoes only subtle changes, appreciable shifts can occur in the setting of a stronger and longer impairment of the tumor on the MC. The ipsilateral hemisphere may serve as a reservoir for functional recovery.
Collapse
Affiliation(s)
- Lucia Bulubas
- Biomagnetic Imaging Lab, Department of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, CA, United States.,Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, United States.,Department of Neurosurgery and TUM-Neuroimaging Center, Klinikum Rechts der Isar, Technische Universität (TU), Munich, Germany.,Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilians Universität (LMU), Munich, Germany.,International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany
| | - Nina Sardesh
- Biomagnetic Imaging Lab, Department of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, CA, United States.,Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, United States
| | - Tavish Traut
- Biomagnetic Imaging Lab, Department of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, CA, United States.,Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, United States
| | - Anne Findlay
- Biomagnetic Imaging Lab, Department of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, CA, United States.,Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, United States
| | - Danielle Mizuiri
- Biomagnetic Imaging Lab, Department of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, CA, United States.,Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, United States
| | - Susanne M Honma
- Biomagnetic Imaging Lab, Department of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, CA, United States.,Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, United States
| | - Sandro M Krieg
- Department of Neurosurgery and TUM-Neuroimaging Center, Klinikum Rechts der Isar, Technische Universität (TU), Munich, Germany
| | - Mitchel S Berger
- Biomagnetic Imaging Lab, Department of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, CA, United States.,Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, United States
| | - Srikantan S Nagarajan
- Biomagnetic Imaging Lab, Department of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, CA, United States.,Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, United States
| | - Phiroz E Tarapore
- Biomagnetic Imaging Lab, Department of Radiology and Biomedical Imaging, University of California San Francisco (UCSF), San Francisco, CA, United States.,Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, United States
| |
Collapse
|
6
|
Zhang L, He X, Liu X, Zhang F, Huang LF, Potter AS, Xu L, Zhou W, Zheng T, Luo Z, Berry KP, Pribnow A, Smith SM, Fuller C, Jones BV, Fouladi M, Drissi R, Yang ZJ, Gustafson WC, Remke M, Pomeroy SL, Girard EJ, Olson JM, Morrissy AS, Vladoiu MC, Zhang J, Tian W, Xin M, Taylor MD, Potter SS, Roussel MF, Weiss WA, Lu QR. Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. Cancer Cell 2019; 36:302-318.e7. [PMID: 31474569 PMCID: PMC6760242 DOI: 10.1016/j.ccell.2019.07.009] [Citation(s) in RCA: 86] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Revised: 04/16/2019] [Accepted: 07/29/2019] [Indexed: 02/05/2023]
Abstract
Progenitor heterogeneity and identities underlying tumor initiation and relapse in medulloblastomas remain elusive. Utilizing single-cell transcriptomic analysis, we demonstrated a developmental hierarchy of progenitor pools in Sonic Hedgehog (SHH) medulloblastomas, and identified OLIG2-expressing glial progenitors as transit-amplifying cells at the tumorigenic onset. Although OLIG2+ progenitors become quiescent stem-like cells in full-blown tumors, they are highly enriched in therapy-resistant and recurrent medulloblastomas. Depletion of mitotic Olig2+ progenitors or Olig2 ablation impeded tumor initiation. Genomic profiling revealed that OLIG2 modulates chromatin landscapes and activates oncogenic networks including HIPPO-YAP/TAZ and AURORA-A/MYCN pathways. Co-targeting these oncogenic pathways induced tumor growth arrest. Together, our results indicate that glial lineage-associated OLIG2+ progenitors are tumor-initiating cells during medulloblastoma tumorigenesis and relapse, suggesting OLIG2-driven oncogenic networks as potential therapeutic targets.
Collapse
Affiliation(s)
- Liguo Zhang
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Xuelian He
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China; Boston Children's Hospital, Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.
| | - Xuezhao Liu
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Feng Zhang
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; State Key Laboratory of Genetic Engineering, Collaborative Innovation Center of Genetics and Development, Department of Biostatistics and Computational Biology, School of Life Sciences, Fudan University, Shanghai 200433, China
| | - L Frank Huang
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Andrew S Potter
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Lingli Xu
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Key Laboratory of Birth Defects, Children's Hospital of Fudan University, Shanghai 201102, China
| | - Wenhao Zhou
- Key Laboratory of Birth Defects, Children's Hospital of Fudan University, Shanghai 201102, China
| | - Tao Zheng
- State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Zaili Luo
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Kalen P Berry
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Allison Pribnow
- Tumor Cell Biology Division, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - Stephanie M Smith
- Tumor Cell Biology Division, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - Christine Fuller
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Blaise V Jones
- Radiology Division, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Maryam Fouladi
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Rachid Drissi
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Zeng-Jie Yang
- Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA 19111, USA
| | - W Clay Gustafson
- Department of Neurology, Pediatrics, and Surgery and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
| | - Marc Remke
- Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany
| | - Scott L Pomeroy
- Boston Children's Hospital, Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA
| | - Emily J Girard
- Division of Pediatric Hematology/Oncology, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle Children's Hospital, Seattle, WA 98145-5005, USA
| | - James M Olson
- Division of Pediatric Hematology/Oncology, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle Children's Hospital, Seattle, WA 98145-5005, USA
| | - A Sorana Morrissy
- Department of Biochemistry and Molecular Biology, The University of Calgary, Calgary, AB T2N 4N1, Canada
| | - Maria C Vladoiu
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada
| | - Jiao Zhang
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada
| | - Weidong Tian
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; State Key Laboratory of Genetic Engineering, Collaborative Innovation Center of Genetics and Development, Department of Biostatistics and Computational Biology, School of Life Sciences, Fudan University, Shanghai 200433, China
| | - Mei Xin
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Michael D Taylor
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada
| | - S Steven Potter
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Martine F Roussel
- Tumor Cell Biology Division, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - William A Weiss
- Department of Neurology, Pediatrics, and Surgery and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
| | - Q Richard Lu
- Experimental Hematology and Cancer Biology, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
| |
Collapse
|
7
|
Pornchai S, Chirappapha P, Pipatsakulroj W, Lertsithichai P, Vassanasiri W, Sitathanee C, Kongdan Y, Sukarayothin T, Leesombatpaiboon M. Malignant transformation of phyllodes tumor: a case report and review of literature. Clin Case Rep 2018; 6:678-685. [PMID: 29636939 PMCID: PMC5889262 DOI: 10.1002/ccr3.1428] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Revised: 10/13/2017] [Accepted: 01/20/2018] [Indexed: 11/09/2022] Open
Abstract
Malignant phyllodes may transform from benign phyllodes; low-aggressive malignant phyllodes tumor is manageable by locally wide excision.
Collapse
Affiliation(s)
- Suragit Pornchai
- Department of Surgery Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand
| | - Prakasit Chirappapha
- Department of Surgery Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand
| | - Wiriya Pipatsakulroj
- Department of Pathology Faculty of Medicine, Ramathibodi Hospital Mahidol University Bangkok Thailand
| | - Panuwat Lertsithichai
- Department of Surgery Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand
| | - Watoo Vassanasiri
- Department of Surgery Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand
| | - Chomporn Sitathanee
- Department of Radiology Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand
| | - Youwanush Kongdan
- Department of Surgery Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand
| | - Thongchai Sukarayothin
- Department of Surgery Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand
| | - Monchai Leesombatpaiboon
- Department of Surgery Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand
| |
Collapse
|
8
|
Aridgides P, Onderdonk B, Cunningham M, Daugherty E, Du L, Bunn WD, Agarwal R, Hahn SS. Institutional experience using interstitial brachytherapy for the treatment of primary and recurrent pelvic malignancies. J Contemp Brachytherapy 2016; 8:173-80. [PMID: 27504125 DOI: 10.5114/jcb.2016.61062] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Accepted: 06/17/2016] [Indexed: 11/17/2022] Open
Abstract
PURPOSE The study assessed the outcomes of patients at a single institution with locally advanced primary and recurrent pelvic malignancies treated with interstitial high-dose-rate (HDR) or low-dose-rate (LDR) brachytherapy (BT), using a modified Syed-Neblett template. MATERIAL AND METHODS Between 1996 and 2010, 60 patients with primary or recurrent pelvic malignancies were treated with interstitial BT. Thirty three patients had primary malignancies with 6.1% being stage I, 33.3% stage II, 45.5% stage III, and 15.2% stage IV; the remaining 27 patients were recurrent malignancies. Fifty four patients received external beam radiotherapy (EBRT) as part of their treatment course. The median EBRT, BT, and EBRT + BT doses were 45 Gy, 20 Gy, and 65 Gy, respectively. Thirty eight patients received concurrent chemotherapy with EBRT. Complete response (CR) was defined by absence of clinical and radiographic disease on first follow-up. Toxicity was graded as per Common Terminology Criteria for Adverse Events, version 4.0. RESULTS The median follow-up was 37 months (4-234 months) and initial CR was achieved in 91%. For primary cancers at diagnosis, 5-year local control (LC), 5-year progression-free survival (PFS), 5-year overall survival (OS) were 65%, 64%, and 42% respectively. For recurrent cancers at diagnosis, 5-year LC, 5-year PFS, and 5-year OS were 80%, 51%, and 37%, respectively. There was a significant difference in both OS and PFS among different tumor sites (p < 0.05), with vaginal cancers having the best 5-year OS (55%) and PFS (84%). There was a total of 1 acute toxicity ≥ grade 3, 6 late grade 3 toxicities, and late grade 4 toxicity. CONCLUSIONS Our series suggests that interstitial BT using a modified Syed-Neblett template is a safe and effective treatment for primary or recurrent pelvic malignancies. This technique allowed effective LC and 97% of patients had preservation of both bladder and rectal function.
Collapse
|
9
|
van den Bent MJ, Gao Y, Kerkhof M, Kros JM, Gorlia T, van Zwieten K, Prince J, van Duinen S, Sillevis Smitt PA, Taphoorn M, French PJ. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol 2015; 17:935-41. [PMID: 25691693 DOI: 10.1093/neuonc/nov013] [Citation(s) in RCA: 124] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2014] [Accepted: 01/13/2015] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The efficacy of novel targeted therapies is often tested at the time of tumor recurrence. However, for glioblastoma (GBM) patients, surgical resections at recurrence are performed only in a minority of patients; therefore, molecular data are predominantly derived from the initial tumor. Molecular data of the initial tumor for patient selection into personalized medicine trials can therefore be used only when the specific genetic change is retained in the recurrent tumor. METHODS In this study we determined whether EGFR amplification and expression of the most common mutation in GBMs (EGFRvIII) is retained at tumor recurrence. Because retention of genetic changes may be dependent on the initial treatment, we only used a cohort of GBM samples that were uniformly treated according to the current standard of care (ie, chemo-irradiation with temozolomide). RESULTS Our data show that, in spite of some quantitative differences, the EGFR amplification status remains stable in the majority (84%) of tumors evaluated. EGFRvIII expression remained similar in 79% of GBMs. However, within the tumors expressing EGFRvIII at initial diagnosis, approximately one-half lose their EGFRvIII expression at tumor recurrence. CONCLUSIONS The relative stability of EGFR amplification indicates that molecular data obtained in the primary tumor can be used to predict the EGFR status of the recurrent tumor, but care should be taken in extrapolating EGFRvIII expression from the primary tumor, particularly when expressed at first diagnosis.
Collapse
Affiliation(s)
- Martin J van den Bent
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.)
| | - Ya Gao
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.)
| | - Melissa Kerkhof
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.)
| | - Johan M Kros
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.)
| | - Thierry Gorlia
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.)
| | - Kitty van Zwieten
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.)
| | - Jory Prince
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.)
| | - Sjoerd van Duinen
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.)
| | - Peter A Sillevis Smitt
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.)
| | - Martin Taphoorn
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.)
| | - Pim J French
- Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.)
| |
Collapse
|
10
|
Moningi S, Armour EP, Terezakis SA, Efron JE, Gearhart SL, Bivalacqua TJ, Kumar R, Le Y, Kien Ng S, Wolfgang CL, Zellars RC, Ellsworth SG, Ahuja N, Herman JM. High-dose-rate intraoperative radiation therapy: the nuts and bolts of starting a program. J Contemp Brachytherapy 2014; 6:99-105. [PMID: 24790628 DOI: 10.5114/jcb.2014.42027] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2013] [Revised: 03/01/2014] [Accepted: 03/28/2014] [Indexed: 12/05/2022] Open
Abstract
High-dose-rate intraoperative radiation therapy (HDR-IORT) has historically provided effective local control (LC) for patients with unresectable and recurrent tumors. However, IORT is limited to only a few specialized institutions and it can be difficult to initiate an HDR-IORT program. Herein, we provide a brief overview on how to initiate and implement an HDR-IORT program for a selected group of patients with gastrointestinal and pelvic solid tumors using a multidisciplinary approach. Proper administration of HDR-IORT requires institutional support and a joint effort among physics staff, oncologists, surgeons, anesthesiologists, and nurses. In order to determine the true efficacy of IORT for various malignancies, collaboration among institutions with established IORT programs is needed.
Collapse
|